Health issues in the framework of Horizon 2020

Research and

Innovation

Rosanna D'Amario

Horizontal Aspects Unit

Health Directorate

Research and Innovation DGRosanna.D'Amario@ec.europa.eu

Incontro presso la

Regione Basilicata

Bruxelles, Belgio

3 ottobre 2013

Seventh Framework Programme for Research and Technology Development (FP7, 2006-2013)

Key figures

6 b€ invested to date

First outcomes(on 281 closed projects)

200

Research and

Innovation

6 b€ invested to date

1,000 projects

11,000 participations

3,500 organisations

130 countries

200 patent applications

9,000 publications

3,3 average SJR* publication

30 spin-offs created

* SCImago Journal Ranking

• Mammography with Molecular Imaging

• Science and engineering to develop machines for breast

MAMMI project

Research and

Innovation

develop machines for breast scanning

• Improve the quality of imaging, detect cancer cells at a much earlier stage

• MAMMI prototype gives quicker follow-up information to monitor how treatment is going

• www.mammiproject.com

• Unbiased biomarkers for the prediction of respiratory disease outcomes (IMI project)

• Building up a much more detailed picture of genetic information in

U-BIOPRED project

Research and

Innovation

picture of genetic information in each individual

• 1 000 patients in order to create a unique database of biological and clinical information

• Determine an individual ‘handprint’ of asthma triggering attacks and driving disease progression

• www.ubiopred.european-lungfoundation.org

1. Excellent science

2. Industrial leadership

Horizon 2020: Three priorities

Research and

Innovation

3. Societal challenges

Horizon 2020 Content & Structure (1)

European Research Council

Frontier research by the best individual teams

Priority 1. Excellent science (~< 32%)

Research and

Innovation

Future and Emerging Technologies

Collaborative research to open new fields of innovation

Marie Curie Actions

Opportunities for training and career development

Research Infrastructures (including e-infrastructure)

Ensuring access to world-class facilities

Leadership in enabling and industrial technologies(ICT, nanotechnologies, materials, biotechnology,

Priority 2. Industrial leadership (~>22%)

Horizon 2020 Content & Structure (2)

Research and

Innovation

(ICT, nanotechnologies, materials, biotechnology,

manufacturing, space)

Access to risk finance

Leveraging private finance and venture capital for

research and innovation

Innovation in SMEs

Fostering all forms of innovation in all types of SMEs

Health, demographic change and wellbeing

Food security, sustainable agriculture, marine

Priority 3. Societal challenges (~> 38%)

Horizon 2020 Content & Structure (3)

Research and

Innovation

Food security, sustainable agriculture, marine and maritime research & the bio-economy

Secure, clean and efficient energy

Smart, green and integrated transport

Climate action, resource efficiency and raw materials

Inclusive societies

Secure societies

Spreading excellence & widening participation

Other (~< 8%)

Horizon 2020 Content & Structure (4)

Research and

Innovation

participation

Science with and for society

European Institute of Technology

Joint Research Centre

Horizon 2020 Modalities (1)• Collaborative research projects require at least three legal

entities from different EU Member States

• Activities requiring at least one legal entity

Research and

Innovation

• European Research Council

• Training & mobility action

• SME instrument

• Programme co-fund

• Coordination & support actions

• Calls for proposals open to organizations from countries outside Member States and Associated Countries

Horizon 2020 Modalities (2)

Investing in partnerships in research and innovation

• Launch of partnerships on 10 July 2013

Research and

Innovation

• 5 Public-private partnerships (proposed in form of Joint Technology Initiatives (JTIs)

• 1 Joint Undertaking

• 4 Joint Programmes with EU Member States

• All together these account for approximately 22 bn €

Timeline 2013:• Jan 2013: First Strategic Programme

• Feb 2013: First meetings of the Horizon 2020 Groups

• Jul 2013: Consultation of HLG MS representatives

• Summer 2013: Draft first work programme

Research and

Innovation

• Summer 2013: Draft first work programme

• Autumn 2013: Inter-service consultation and consultation of the Member States

• 10 Dec 2013: Adoption of the work programme and publication of the calls for proposals

• 2014: Expected deadline …

Societal Challenge Health,Demographic Change and Wellbeing (1)

• Understanding the determinants of health (including environmental and climate related factors), improving health promotion and disease prevention;

Research and

Innovation

• Developing effective screening programmes and improving the assessment of disease susceptibility

• Improving surveillance and preparedness

• Understanding disease

• Developing better preventive vaccines

• Improving diagnosis

• Using in-silico medicine for improving disease management and prediction

Societal Challenge Health,Demographic Change and Wellbeing (2)

• Treating disease

• Transferring knowledge to clinical practice and scalable innovation actions

• Better use of health data

Research and

Innovation

• Better use of health data

• Improving scientific tools and methods to support policy making and regulatory needs

• Active ageing, independent and assisted living

• Individual empowerment for self-management of health

• Promoting integrated care

• Optimising the efficiency and effectiveness of healthcare systems and reducing inequalities

Proposed Work Programme Cycle

2014 2015 2016 2017 2018 2019 2020

Strategic Programme

Research and

Innovation

Work Programme 1(plus tentative information for2016)

Strategic Programme

Work Programme 2(plus tentative information for2018)

Strategic Programme

Work Programme 3(plus tentative information for2020)

Work Programme4

Special supportfor SMEs in Horizon 2020

• ~5 billion EUR in H2020

• Inspired by the US model "SBIR"

Research and

Innovation

"SBIR"

• Challenge driven, bottom up

• A single company can be funded

• 3 phases / 3 entry points:

• Concept and feasibility assessment • R&D, demonstration, market

replication • Commercialization

A few points to remember

• 1b€/year devoted to health research in Horizon 2020

• One rule: Minimum 3 partners from 3 EU countries + anyone else from

Research and

Innovation

EU countries + anyone else from anywhere in the world

• Funding: 3-12 m€ per project 100%+25% reimbursement rate

• Project duration: 3-5 years

• Call publication: 11 December 2013

How to apply in Horizon 2020?

1. Read the call, identify a relevant topic

Research and

Innovation

2. Find relevant partners

3. Write and submit your proposal

4. Get funded (~10% success rate)!

International K.O. Mouse Consortium

International Human Microbiome Consortium

Continued international cooperation

Research and

Innovation

International Cancer Genomics Consortium

International Human Epigenome Consortium

International Rare Disease Research

Consortium

International Initiative for Traumatic Brain

Injury Research

© rtg

uest/F

oto

lia.c

om

Global Alliance for Chronic Diseases

200 New Therapies

IRDiRC vision and 2020 goals

Research and

Innovation

Means to Diagnose Most Rare Diseases

© Y

uri

Arc

urs

/Foto

lia.c

om

© n

yul/

Foto

lia.c

om

IRDiRC: 35 members

Europe

E-RARE 2 Consortium (EU)

European Commission (EU)

EURORDIS (EU)

French Muscular Dystrophy Association (FR)

French National Research Agency (FR)

German Federal Ministry of Education and research (DE)

North America

Canadian Institutes for Health Research (CA)

FDA Orphan Products Grants Program (US)

Genome Canada (CA)

Genetic Alliance (US)

Mendelian Disorders Genome Centres (US)

National Centre for Translational Sciences (US)

Asia

BGI (CN)

Chinese Rare

Research and

Innovation

and research (DE)

Istituto Superiore di Sanità (IT)

Italian Telethon Foundation (IT)

Lysogene (FR)

Netherlands Organisation for Health Research and Development

Prosensa (NL)

Spanish Carlos III Health Institute (ES)

UK National Institute for Health Research (UK)

National Cancer Institute (US)

National Institute of Neurological Disorders and Stroke (US)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (US)

National Institute of Child Health and Human Development (US)

National Eye Institute (US)

NKT Therapeutics (US)

NORD (US)

Office of Rare Diseases (US)

PTC Therapeutics (US)

Sanford Research (US)

Shire (US)

© rtg

uest/F

oto

lia.c

om

Australia

National Health and Medical Research Council

Western Australian Department of Health

Chinese Rare Disease Consortium (CN)

Korea National Institute of Health (KR)

Global Alliance for ChronicDiseases: Global health challenges

Why international cooperation ?

• Health research is a priority for all of us• Addressing global challenges needs critical mass of resources,

Research and

Innovation

• Addressing global challenges needs critical mass of resources, expertise, infrastructures, patients

• Need for data sharing, exchange of good practices• Sharing work and costs

Strategic objectives

• Tackle chronic non-communicable diseases• Contribute towards the MDGs• GACD is a unique model of pairing HIC with LMIC researchers

More @ http://www.gacd.org/

Global Research Collaboration for Infectious Disease Preparedness

Objective: to coordinate and initiate researchefforts addressing infectious epidemic within 48hours after an outbreak

Research and

Innovation

hours after an outbreak

• Launched in Brussels February 2013

• Current participating countries: Australia, Canada, China,France, UK, US, Sweden

• Interested funding bodies are invited to participate -nextmeeting 9-10 October 2013 Annecy, France

• Contact point: RTD-Unit F.3 Infectious Diseases andPublic Health, Line Matthiessen, Head of Unit

EDCTP: The European and DevelopingCountries Clinical Trials Partnership

• Established in 2003 as Part of the Union's response to the global health crisis caused by HIV/AIDS, malaria and tuberculosis

• Collaboration between the EC, 16 European countries and 48 sub-Saharan African

Research and

Innovation

countries and 48 sub-Saharan African countries

• Pioneered joint programming, i.e. the coordination, alignment and integration of European national research programmes.

• Objectives:

• Funding clinical trials on HIV/AIDS, TB and Malaria

• Strengthening related capacities

EDCTP2 - Renewal of the "European andDeveloping Countries Clinical Trials Partnership"

• Second phase of EDCTP expected to be launched early 2014 with:

a) extended scope to include neglected infectious diseases, all clinical phases, diagnostics and delivery optimization

Research and

Innovation

diagnostics and delivery optimization

b) increased budget

c) extended duration

• Political and financial up-front commitment from 17 European countries of more than €594 million

• EU will provide matching co-funding through Horizon 2020

• International partners welcomed

IMI: Innovative Medicines Initiative

• New type of public/private

partnership

• 1:1 funding, joint decision making

Research and

Innovation

• All EU funding goes to SMEs,

academia, patient organisations

and regulatory agencies

• Large pharmaceutical industry,

represented by EFPIA, contributes

in-kind

1 billion EUR 1 billion EUR

2 billion EUR

In the pipeline: IMI2

• Commission proposal published on 10 July

• Mission: create an even more powerful research and innovation machine – with broader objectives and a wider range of activities and partners

Research and

Innovation

• Proposed budget from public and private partners: 3.5 Billion Euro

• Key objectives:

• Pave the way for the breakthroughvaccines, medicines and treatmentswhich we will need in the near future

• Enable top quality research andinnovations with great public healthbenefits and commercial possibilities

Grazie dell'attenzione!

Research and

Innovation

Per ulteriori informazioni:

www.ec.europa.eu/research/horizon2020